JP2012504602A - Ｃ型肝炎抗体およびその使用 - Google Patents

Ｃ型肝炎抗体およびその使用 Download PDF

Info

Publication number
JP2012504602A
JP2012504602A JP2011530033A JP2011530033A JP2012504602A JP 2012504602 A JP2012504602 A JP 2012504602A JP 2011530033 A JP2011530033 A JP 2011530033A JP 2011530033 A JP2011530033 A JP 2011530033A JP 2012504602 A JP2012504602 A JP 2012504602A
Authority
JP
Japan
Prior art keywords
hcv
antibody
antibodies
epitope
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011530033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504602A5 (OSRAM
Inventor
スティーブン ファン，
ツェン−ヨン ケック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2012504602A publication Critical patent/JP2012504602A/ja
Publication of JP2012504602A5 publication Critical patent/JP2012504602A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011530033A 2008-10-05 2008-10-05 Ｃ型肝炎抗体およびその使用 Withdrawn JP2012504602A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2012504602A true JP2012504602A (ja) 2012-02-23
JP2012504602A5 JP2012504602A5 (OSRAM) 2012-11-01

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530033A Withdrawn JP2012504602A (ja) 2008-10-05 2008-10-05 Ｃ型肝炎抗体およびその使用

Country Status (12)

Country Link
US (1) US8858947B2 (OSRAM)
EP (1) EP2331573A4 (OSRAM)
JP (1) JP2012504602A (OSRAM)
KR (1) KR20110061624A (OSRAM)
CN (1) CN102197050A (OSRAM)
AU (1) AU2008362482A1 (OSRAM)
BR (1) BRPI0823197A2 (OSRAM)
CA (1) CA2738644A1 (OSRAM)
EA (1) EA201170353A1 (OSRAM)
IL (1) IL212040A0 (OSRAM)
MX (1) MX2011003613A (OSRAM)
WO (1) WO2010039154A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES HAVING INHIBITION ACTIVITY OF HEPATITIS C VIRUS (HCV) INFECTION AND USE THEREOF
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
JP6158171B2 (ja) 2011-05-02 2017-07-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成ｃ型肝炎ゲノム、並びに、その製造方法及びその使用
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR102640157B1 (ko) * 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127170A4 (en) * 1998-11-05 2005-04-27 Univ Leland Stanford Junior HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質

Also Published As

Publication number Publication date
BRPI0823197A2 (pt) 2015-06-23
CN102197050A (zh) 2011-09-21
CA2738644A1 (en) 2010-05-08
EA201170353A1 (ru) 2011-12-30
MX2011003613A (es) 2011-08-03
EP2331573A1 (en) 2011-06-15
AU2008362482A1 (en) 2010-04-08
US20120039846A1 (en) 2012-02-16
KR20110061624A (ko) 2011-06-09
IL212040A0 (en) 2011-06-30
US8858947B2 (en) 2014-10-14
EP2331573A4 (en) 2012-09-05
WO2010039154A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
US8858947B2 (en) Hepatitis C antibodies and uses thereof
JP5642972B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
JP5698137B2 (ja) Ｃ型肝炎ウイルス感染の阻害のためのモノクローナル抗クローディン１抗体
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
US20240050565A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
US20140322204A1 (en) Treatment and prevention of viral infections
CN102143975B (zh) 特异性配体在msrv相关疾病中的治疗用途
JP2012513457A (ja) Ｈｃｖ感染の治療的処置および予防のための医薬としての抗ｈｃｖモノクローナル抗体
US20100104555A1 (en) HCV neutralizing epitopes
JP2006504645A (ja) 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
WO2010047829A1 (en) Mutant hepatitis c virus e2 polypeptides for hcv treatment
CN103429265A (zh) 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物
AU2013251185A1 (en) Human antibodies against hepatitis C virus (HCV) and uses thereof
HK1138297B (en) Human antibodies against hepatitis c virus (hcv) uses thereof
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods

Legal Events

Date Code Title Description
A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20121227

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130108